← Back to Clinical Trials
Recruiting NCT05991193

NCT05991193 A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05991193
Status Recruiting
Phase
Sponsor Hunan Province Tumor Hospital
Condition NSCLC
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-12-29
Primary Completion 2025-08-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-12-29 with a primary completion date of 2025-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Eligibility Criteria

Inclusion Criteria: * Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together. * Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC). * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion. Exclusion Criteria: * None

Contact & Investigator

Central Contact

Yongchang Zhang, MD

✉ zhangyongchang@csu.edu.cn

📞 +8613873123436

Frequently Asked Questions

Who can join the NCT05991193 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05991193 currently recruiting?

Yes, NCT05991193 is actively recruiting participants. Contact the research team at zhangyongchang@csu.edu.cn for enrollment information.

Where is the NCT05991193 trial being conducted?

This trial is being conducted at Changsha, China.

Who is sponsoring the NCT05991193 clinical trial?

NCT05991193 is sponsored by Hunan Province Tumor Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology